Dr. Rankovic is a member of the Crazy 8 team that is studying Small Moledule Degraders for Targeting Transcription Factor Drivers of Childhood Cancer. Prior to joining St. Jude in late 2016, Zoran was medicinal chemistry director and research fellow in Organon, Schering-Plough, Merck and most recently Eli Lilly. During his industrial career Zoran direct teams that delivered multiple clinical candidates over a range of therapeutic areas including neurooncology, neurodegeneration, psychiatry and cardiovascular disorders. Zoran authored and co-authored over 100 scientific publications, patents, and book chapters.

Since joining St. Jude, Zoran’s research interests focus on the development of small molecule epigenetic modulators and protein degraders for the treatment of pediatric cancers such as medulloblastoma and acute leukemia.